ADC Therapeutics Aktie
| 3,70USD | -0,26USD | -6,57% |
WKN DE: A2PSR8 / ISIN: CH0499880968
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 312 | 317 | 162 | 265 | 193 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,11 | 0,66 | 0,43 | 0,27 | 0,42 |
Bilanz (in Mio. USD) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 525 | 446 | 336 | 307 | 306 |
| Summe Anlagevermögen | 93 | 83 | 18 | 15 | 18 |
| Summe Aktiva | 618 | 529 | 355 | 322 | 324 |
Bilanz (in Mio. USD) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 452 | 440 | 503 | 525 | 510 |
| Summe Eigenkapital | 166 | 89 | -148 | -203 | -186 |
| Summe Passiva | 618 | 529 | 355 | 322 | 324 |
Adresse
| Biopôle, 1066 Epalinges | |
| Telefon | +41 (212) 653-02-00 |
| Internet | http://www.adctherapeutics.com |
Management
|
Ameet Mallik
President, Chief Executive Officer & Director |
|
David S. Ege
Chief Technical Officer |
|
Jean Pierre Bizzari
Independent Non-Executive Director |
|
Jose Carmona
Chief Financial Officer |
|
Kimberly Pope
Chief People Officer |
|
Kristen Harrington-Smith
Chief Commercial Officer & Senior Vice President |
|
Mohamed Zaki
Chief Medical Officer |
|
Nicole Riley
Investor Relations Contact |
|
Patrick van Berkel
Chief Scientific Officer |
|
Peter Hug
Vice Chairman |
|
Peter J. Graham
Secretary & Chief Legal Officer |
|
Robert W. Azelby
Independent Non-Executive Director |
|
Ron Squarer
Chairman |
|
Timothy P. Coughlin
Non-Executive Director |
|
Tyrell J. Rivers
Independent Non-Executive Director |
|
Victor Sandor
Independent Non-Executive Director |
|
Viviane Monges
Independent Non-Executive Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.